Genus plc Achieves FDA Approval for PRRS Resistant Pig

Genus plc ( (GB:GNS) ) just unveiled an update.

Genus plc has received FDA approval for its PRRS Resistant Pig gene edit, a significant milestone towards commercializing this innovation in the U.S. food supply chain. This approval is pivotal for the company as it seeks similar regulatory approvals in key export markets like Mexico, Canada, and Japan, and has already received positive determinations from Brazil, Colombia, and the Dominican Republic. The PRRS disease is a major concern in the pork industry, increasing antibiotic use significantly, and Genus’s breakthrough is expected to have a substantial impact on reducing these issues, marking a significant advancement for the industry.

Spark’s Take on GB:GNS Stock

According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.

Genus plc’s overall stock score reflects moderate financial performance with stable balance sheet strengths but concerns over cash flow and revenue. Although the earnings call provided positive strategic insights, technical analysis and valuation metrics indicate caution, suggesting the stock may face challenges in achieving significant upward momentum.

To see Spark’s full report on GB:GNS stock, click here.

More about Genus plc

Genus plc is a leading global animal genetics company that specializes in biotechnology to advance animal breeding and genetic improvement. The company provides value-added products for livestock farming and food producers, operating in the dairy, beef, and pork sectors. Genus’s products, including semen, embryos, and breeding animals, are sold in over seventy-five countries under the trademarks ‘ABS’ for dairy and beef cattle and ‘PIC’ for pigs. The company is headquartered in Basingstoke, UK, with research labs in Madison, Wisconsin, USA.

YTD Price Performance: 4.05%

Average Trading Volume: 141,270

Technical Sentiment Signal: Strong Buy

Current Market Cap: £1.05B

For an in-depth examination of GNS stock, go to TipRanks’ Stock Analysis page.